Analyst Issues Buy Rating on Alector Amid Promising Biomarker Research and Positive FDA Interactions
TD Cowen Remains a Buy on Alector (ALEC)
Alector Analyst Ratings
Goldman Sachs Maintains Alector(ALEC.US) With Sell Rating
Goldman Sachs Keeps Their Sell Rating on Alector (ALEC)
Alector Analyst Ratings
Barclays Sticks to Their Buy Rating for Alector (ALEC)
Alector Analyst Ratings
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Revance Therapeutics (RVNC) and Alector (ALEC)
Optimistic Buy Rating for Alector's AL002 Based on Promising Alzheimer's Disease Trial Biomarkers and TREM2 Signaling Efficacy
Alector: Cautious Hold Rating Ahead of Key Clinical Trial Milestones and Financial Assessment
Alector (ALEC) Receives a Buy From Barclays
TD Cowen Sticks to Their Buy Rating for Alector (ALEC)
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Alector (ALEC) and Cytokinetics (CYTK)
Alector's Promising Pipeline and Market Potential Affirm Buy Rating
Analysts Offer Insights on Healthcare Companies: Alector (ALEC), Viking Therapeutics (VKTX) and Zimmer Biomet Holdings (ZBH)
Alector (ALEC) Gets a Buy From BTIG
A Buy Rating for Alector: Innovating in Neurodegeneration With a Promising Immuno-Neurology Pipeline
Stifel Upgrades Alector to Buy, Stock Rallies 18%
Stifel Upgrades Alector to Buy, Raises Price Target to $15